Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement

Naiba Nabieva 1,2 and Peter A. Fasching 1,*

1 Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany; naiba.nabieva@fau.de
2 Novartis Oncology, Novartis Pharma GmbH, 90429 Nuremberg, Germany
* Correspondence: peter.fasching@uk-erlangen.de; Tel.: +49-9131-85-36167; Fax: +49-9131-85-33938

Simple Summary: Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that have been used for decades in the treatment of patients with endocrine-therapy-sensitive breast cancer. Due to the findings of recent studies and the approval of novel substances for the treatment of this patient population, the established standards of endocrine therapy are changing. Considering signaling pathways such as the PI3K/AKT/mTOR or the CDK4/6 pathway, as well as resistance mechanisms and substances analyzed against these, endocrine treatment of hormone-receptor-positive breast cancer is on the brink of a new era. This review provides an overview of the history of endocrine treatment, clarifies its role in the present standard of care, and discusses the possibilities of improvement.

Abstract: Purpose of review: Due to the findings of current studies and the approval of novel substances for the therapy of hormone-receptor-positive breast cancer patients, the established standards of endocrine treatment are changing. The purpose of this review is to give an overview of the history of endocrine treatment, to clarify its role in the present standard of care, and to discuss the possibilities of improvement. Recent findings: Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that have been used for decades in the therapy of hormone-receptor-positive breast cancer patients. However, since a relevant number of women suffer at some point from disease recurrence or progression, several novel substances are being investigated to overcome resistance mechanisms by interfering with certain signaling pathways, such as the PI3K/AKT/mTOR or the CDK4/6 pathways. mTOR and CDK4/6 inhibitors were the first drugs approved for this purpose and many more are in development. Summary: Endocrine treatment is one of the best tolerable cancer therapies available. Continuous investigation serves to improve patients’ outcomes and modernize the current standard of care. Considering the resistance mechanisms and substances analyzed against these, endocrine treatment of hormone-receptor-positive breast cancer is on the brink of a new era.

Keywords: breast cancer; endocrine treatment; tamoxifen; aromatase inhibitor; fulvestrant; CDK 4/6 inhibitor; ribociclib; palbociclib; abemaciclib; PI3K inhibitor; alpelisib; mTOR inhibitor; SERD; compliance

1. Introduction

Endocrine treatment (ET) of breast cancer (BC) was one of the first implementations of an individualized treatment of cancer. At the end of the 19th century, Sir George Thomas Beatson first discovered the positive influence of a bilateral oophorectomy on the development of breast cancer lesions in women with advanced disease, and ET was born [1]. Over time, research on antihormonal substances progressed and it was discovered that only patients with an expression of hormone receptors received any benefit from...
therapy with tamoxifen [2]. The implementation of a test that assesses the expression of hormone receptors and enables an appropriate therapy decision [3] was, besides testing for the human epidermal growth factor receptor 2 (HER2) and a subsequent trastuzumab treatment [4], the beginning of individualized therapies for BC patients.

The efficacy of ET was first evaluated in women with advanced breast cancer (aBC). In addition to tamoxifen and the three aromatase inhibitors (AIs) anastrozole, letrozole, and exemestane, with fulvestrant, a selective estrogen receptor degrader (SERD), there are several ET options available for aBC patients [5–7]. While in a metastatic treatment setting the primary objective is to improve progression-free survival (PFS) and overall survival (OS), while maintaining quality of life (QoL) at the same time, the goal of adjuvant ET is to reduce the disease recurrence and mortality rates of hormone-receptor-positive early breast cancer (eBC) patients [2,8] with an acceptable risk–benefit ratio. In premenopausal women with eBC and a low risk of disease recurrence, tamoxifen is the preferred adjuvant ET [2,9]; in those with a high risk, the combination of tamoxifen or an AI with ovarian function suppression (OFS) is recommended [10]; and in postmenopausal eBC patients, therapy with an AI is the treatment of choice [10], since it shows superior results regarding disease-free survival (DFS) [8,11–15] and, in some trials, OS as well [8,13,15].

Since a relevant number of women treated with ET suffer at some point from disease recurrence or progression, novel substances are being investigated to overcome resistance mechanisms by interfering with certain signaling pathways and supporting the efficacy of established therapies [16,17].

This review is designed to give an overview on the recent history of ET, to clarify its role in the present therapy of hormone-receptor-positive HER2-negative BC, and to discuss future directions for further improvement.

2. History and the State of the Art of Endocrine Treatment

The beginnings of ET can be dated back to the early 1970s. In the following, the main substances that have been used for decades and still currently build the foundation of any endocrine-based therapy are presented.

2.1. Tamoxifen

When the selective estrogen receptor modulator (SERM) tamoxifen first showed positive results in the therapy of hormone-receptor-positive aBC, its development gained more attention [18]. In several randomized trials, tamoxifen demonstrated comparable efficacy with megestrol acetate, which was used to treat BC patients previously. However, tamoxifen presented a better side effect profile, which eventually led to the approval of this therapy in the United States in 1977 [19]. Further analyses showed a reduction in the risk of recurrence when tamoxifen was given as an adjuvant treatment. The optimal therapy duration was subject to several subsequent investigations, which showed a significant trend towards a greater effect with longer treatment, so for many years an adjuvant therapy of five years of tamoxifen was recommended [2].

Later, the ATLAS and aTTom trials demonstrated that an extension in treatment from five to up to ten years leads to a further survival benefit [20,21]; such a treatment duration then became an option, especially for premenopausal patients with a high risk of recurrence [10,22]. In these women, additional ovarian function suppression is also recommended [10,22]. The SOFT and TEXT trials showed improved disease-free survival and overall survival, adding OFS to a treatment with tamoxifen alone [23–25].

2.2. Aromatase Inhibitors

In the 1970s, investigators also found that estrogen synthesis takes place not only in the ovaries and adrenal glands, but, in postmenopausal women, also in muscle, liver, and adipose tissues by the catalysis of androgens to estrogens through aromatase, an enzyme of the cytochrome P450 family. This knowledge led to the development of the third-generation AIs anastrozole, letrozole, and exemestane to reduce estrogen levels in
hormone-receptor-positive BC patients [26]. The comparison between AIs and tamoxifen in postmenopausal women with aBC demonstrated the superiority of AIs and resulted in their approval and establishment in this treatment setting [5–7]. Regarding the adjuvant therapy of postmenopausal women suffering from hormone-receptor-positive eBC and the improvement of DFS, AIs’ effect was later analyzed and found again to be superior compared to tamoxifen, resulting in an extension of the approval [8,11–15]. Decades later, in the FATA-GIM3 as well as in the FACE trials, a difference in efficacy between each AI could not be found [27,28].

According to current results, the optimal therapy duration of AIs seems to be at least five years, but due to an ongoing risk of recurrence after the first five years in patients with high-risk BC, a prolongation for up to 10 years in terms of an extended ET seems to further improve DFS [10,29,30]. Nevertheless, statements regarding the exact duration of the extended treatment are partially contradictory, since there are studies that have shown a non-inferiority of seven to eight years of ET compared to 10 years [31] or even no significant difference at all when comparing five versus ten years of AI therapy [32]. An intermittent approach in the SOLE study, however, did not show superior results compared to continuous AI intake [33]. Furthermore, as with tamoxifen, in younger premenopausal women with a high risk of disease recurrence, a combined treatment with an AI and OFS is feasible. This has been shown to improve DFS, but not OS, compared to tamoxifen and OFS as well as to tamoxifen alone [24,25].

2.3. Fulvestrant

Another option of ET is fulvestrant, the only approved SERD for the therapy of hormone-receptor-positive aBC in postmenopausal women to date, which joined the ET family in the early years of the millennium. Trials investigating the outcomes of patients that received fulvestrant versus an AI demonstrated that it is at least as effective and safe [34], or even superior [35,36]. This is why it was approved and recommended for the therapy of aBC, especially in the first or second treatment line [34,37,38]. Further analyses included the dosage at which its effect on patients’ outcomes is most favorable, and found that fulvestrant given at 500 mg achieves better results than at 250 mg [34,36]; this then became part of the guidelines [37].

Moreover, ET combination strategies are also of interest. The addition of fulvestrant to an AI, for instance, seems to be associated with an OS benefit, but since it results in a higher incidence of relatively serious adverse events (AEs), this combination treatment did not become the standard of care [39].

3. Modern Approaches in Advanced Breast Cancer

Several pathways, resistance mechanisms, and mutations are described in the literature as reasons for disease recurrence or progression. The major pathways include the phosphatidylinositol 3-kinase/AKT murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway, as well as the cyclin-dependent kinase 4/6 (CDK4/6) cell cycle pathway [16,17]. Figure 1 provides an overview of the main cell proliferation mechanisms.

3.1. PI3K/AKT/mTOR Signaling Pathway

One of the main substances acting within the PI3K/AKT/mTOR pathway is the mTOR inhibitor everolimus. It was the first agent of the inhibitors of this signaling pathway approved for the therapy of hormone-receptor-positive aBC. Everolimus showed an increase in the time to progression when given in combination with the steroidal AI exemestane [40,41], while a significant improvement in OS could not be demonstrated in the BOLERO-2 trial [42]. The dual mTOR inhibitor vistusertib that, in contrast to everolimus, inhibits not only the mTOR complex 1, but also 2, did not result in a PFS benefit when added to fulvestrant [43]. However, in a small study, sirolimus, also an agent from the
mTOR inhibitor family, has so far achieved positive results regarding the PFS, comparable to those under everolimus [44].

Another group of agents inhibiting the above-mentioned signaling pathway that were developed to overcome endocrine resistance are PI3K inhibitors. Buparlisib, such a PI3K inhibitor, was analyzed together with fulvestrant in postmenopausal women with hormone-receptor-positive aBC. At first showing promising results in preliminary studies, its development was later omitted due to a higher rate of grade three and four AEs, seen in the phase III trials BELLE-2 and -3 [45–47]. Another PI3K inhibitor that failed to become standard-of-care treatment due to later-phase results is taselisib. Its investigation within the phase III SANDPIPER study led to the conclusion that the combination of taselisib and fulvestrant has no clinical utility given its safety profile and a modest PFS benefit of two months compared to fulvestrant alone [48]. However, in contrast to the above-mentioned substances, with alpelisib a PI3K inhibitor is available for the PIK3CA-mutated, postmenopausal aBC patient, since it shows a statistically significant benefit regarding PFS as well as a meaningful clinical benefit in OS, with an acceptable safety profile at the same time [49–52]. Its approval is the result of the SOLAR-1 trial, based on which, in current treatment guidelines, the substance is recommended for the therapy of women as well as men with this specific tumor type [53]. Further trials with different treatment combination strategies including CDK4/6 inhibitors, fulvestrant, and alpelisib or novel PI3K inhibitors, such as inavolisib and copanlisib, or even combined PI3K/mTOR inhibitors, such as gedatolisib for instance, will deliver more information about the efficacy and safety of this drug family [54–56].
The last group that interferes with this signaling pathway is AKT inhibitors, which is the only group in this pathway that has no approved drug to date. The main substances under current investigation are ipatasertib and capivasertib. Capivasertib is an AKT inhibitor that demonstrated activity in AKT1-mutant hormone-receptor-positive aBC, not only in combination with fulvestrant but also in terms of a monotherapy [57]. PFS in patients administered capivasertib and fulvestrant was significantly longer than under fulvestrant with a placebo in the phase II trial FAKTION [58]. Therefore, the substance is currently being investigated in the later-phase trial program CAPItello [59]. Ipatasertib, however, failed to prove efficacy regarding PFS when combined with paclitaxel versus paclitaxel alone in the treatment of triple-negative as well as hormone-receptor-positive aBC in the phase III IPATunity130 study [60,61]. Nevertheless, in hormone-sensitive BC patients, research on ipatasertib in combination with fulvestrant and/or a CDK4/6 inhibitor is proceeding [56].

3.2. CDK4/6 Signaling Pathway

In 47 human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer, palbociclib was tested and showed a differential effect on those cell lines with an emphasize on hormone-receptor-positive and HER2-amplified ones [62]. On the basis of this effect, the further development of CDK4/6 inhibition started [63,64]. In the past few years, the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib have been approved and recommended [53] for the treatment of hormone-receptor-positive, HER2-negative aBC on the basis of three large phase III trial programs, PALOMA, MONALEESA, and MONARCH, since all trials show a significant improvement in PFS when combined with an AI or fulvestrant [65–71] (Table 1). Regarding PFS, CDK4/6 inhibitors in the first and second treatment lines are also superior compared to chemotherapy [72], hence their use increased substantially in the first years after becoming available, while fewer patients started receiving chemotherapy [73,74]. Meanwhile, some of the trials even provided significantly improved OS data, which is an exceptional result in this treatment setting. In the MONARCH-2 trial, for instance, the addition of abemaciclib to fulvestrant significantly prolonged OS in women who had not received chemotherapy and had a maximum of one prior ET for aBC [75]. Under palbociclib and fulvestrant, however, OS was prolonged but did not reach formal statistical significance in the PALOMA-3 trial [76]. There are further results on the efficacy of palbociclib from the PEARL trial, comparing ET with the CDK4/6 inhibitor to chemotherapy. Compared to capecitabine, palbociclib and ET did not demonstrate superiority regarding OS [77]. Besides, in both the study program trials, namely the MONARCH-3 for abemaciclib and PALOMA-2 for palbociclib, any data on OS have not been reported yet and further results are expected. For ribociclib, however, a total of three trials have reported data on OS and show a consistent significant benefit that is independent from its use in the first or second treatment line, pre- or postmenopausal women, or with an AI or fulvestrant as ET partner [78–80]. In the MONALEESA-2 study, postmenopausal patients under first-line ribociclib and letrozole achieved a median OS of 63.9 months, the longest OS data reported for aBC to date [78]. Still, the question remains how to treat patients that progress under CDK4/6 inhibition. Novel strategies include, among others, the continuation of CDK4/6 inhibitors through progression as well as triple combinations with PI3K or checkpoint inhibitors [81].
**Table 1. Efficacy of CDK4/6 inhibitors in hormone-receptor-positive, HER2-negative aBC phase III trials (in alphabetical and numerical order).**

| Treatment Combination | Study Name | Sample Size | Randomization | Median PFS in Months | Median OS in Months | Statistically Significant as per Protocol | 95% CI   | Statistically Significant as per Protocol | 95% CI   |
|-----------------------|------------|-------------|---------------|----------------------|---------------------|------------------------------------------|----------|------------------------------------------|----------|
| ET +/- abemaciclib    | MONARCH-2 [68,75] | 669 | 2:1 | 16.4 | 9.3 | 0.55 | 0.45–0.68 | Yes | 46.7 | 37.3 | 0.76 | 0.61–0.95 | Yes |
|                       | MONARCH-3 [69] | 493 | 2:1 | 28.2 | 14.8 | 0.54 | 0.42–0.70 | Yes | Not reported yet | |
| ET +/- dalpicillic    | DAWNA-1 [82] | 361 | 2:1 | 13.6 1 | 7.7 1 | 0.45 1 | 0.32–0.64 1 | Yes 1 | Not reported yet | |
| ET +/- palbocillic    | PALOMA-2 [66] | 666 | 2:1 | 24.8 | 14.5 | 0.58 | 0.46–0.72 | Yes | Not reported yet | |
|                       | PALOMA-3 [67,76] | 521 | 2:1 | 9.5 | 4.6 | 0.46 | 0.36–0.59 | Yes | 34.9 | 28.0 | 0.81 | 0.64–1.03 | No |
|                       | MONALEESA-2 [71,78] | 668 | 1:1 | 25.3 | 16.0 | 0.57 | 0.46–0.70 | Yes | 63.9 | 51.4 | 0.76 | 0.63–0.93 | Yes |
|                       | MONALEESA-3 [65,79] | 726 | 2:1 | 20.5 | 12.8 | 0.59 | 0.48–0.73 | Yes | 53.7 | 41.5 | 0.73 | 0.59–0.90 | Yes |
|                       | MONALEESA-7 [70,80] | 672 | 1:1 | 23.8 | 13.0 | 0.55 | 0.44–0.69 | Yes | 58.7 | 48.0 | 0.76 | 0.61–0.96 | Yes |

HER2: human epidermal growth factor receptor 2; aBC: advanced breast cancer; CI: confidence interval; ET: endocrine treatment; HR: hazard ratio; OS: overall survival; and PFS: progression-free survival. 1 As assessed by an independent review committee.
3.3. Selective Estrogen Receptor Downregulation

Besides the PI3K/AKT/mTOR and CDK4/6 signaling pathways, the downregulation of estrogen receptor expression also plays a significant role in the treatment of hormone-receptor-positive BC. As mentioned above, fulvestrant is the only approved SERD for the therapy of postmenopausal aBC patients to date. However, since there is a lack of oral bioavailability of fulvestrant, therefore requiring intramuscular injection of it [83,84], other novel SERDs with the potential of oral bioavailability are being investigated [85–89] (Table 2). A first-in-human study on the SERD AZD9496, for instance, showed an acceptable safety profile and a prolongation of disease stabilization in women with hormone-receptor-positive aBC [90], but its preoperative influence on estrogen receptor expression was not superior to fulvestrant within a recent window of an opportunity trial in eBC [91]. Giredestrant, however, has also been analyzed in a similar treatment setting within the neoadjuvant phase II coopERA trial. Compared to anastrozole, after 2 weeks of giredestrant a greater relative reduction in Ki-67 as well as a greater number of tumors achieving complete cell cycle arrest were observed [92]. Results from the phase I/II AMEERA-I study on the combination of amcenestrant with palbociclib in postmenopausal women with aBC also showed encouraging response and clinical benefit rates [93]. The EMERALD, however, is the first phase III trial with an oral SERD that could show positive results in aBC patients under elacestrant compared to those under standard of care ET regardless of ESR1 mutations [94].

Table 2. Selection of novel SERDs under clinical development in phase III eBC/aBC trials (in alphabetical order; based on clinicaltrials.gov, accessed on 22 September 2021) [56].

| Substance Name     | Original Substance Code | Trial Program                  |
|--------------------|-------------------------|--------------------------------|
| Amcenestrant [85]  | SAR439859               | AMEERA                         |
| Camizestrant [88]  | AZD9833                 | SERENA                         |
| Elacestrant [87]   | RAD1901                 | EMERALD                        |
| Giredestrant [86]  | GDC-9545                | persevERA (aBC) and lidERA (eBC) |
| 1                  | LY3484356 [89]          | EMBER                          |

SERD: selective estrogen receptor degrader; eBC: early breast cancer; and aBC: advanced breast cancer. 1 Data unknown at the time of writing this manuscript.

3.4. Germline BRCA1/2 Mutation

Developed on the basis of germline BRCA1/2 mutations and their role in tumor pathology, poly (ADP-ribose) polymerase (PARP) inhibitors are a further therapy option for patients with advanced HER2-negative disease, including both triple-negative and hormone-receptor-positive BC patients, who make up about 50% of all aBC patients [95]. The OlympiAD trial for olaparib [96] and the EMBRACA trial for talazoparib [97] showed an improvement concerning PFS over a chemotherapy of physicians’ choice. However, in both studies a significant influence on OS was not observed [98,99].

4. Adverse Events of and Adherence to Endocrine Treatment

ET is standard in early and advanced therapy settings [10,100–105], and therefore the impact of these therapies effects a large number of patients for a long time. The main side effects of clinical interest are musculoskeletal symptoms [106,107], thromboembolic events [108], hot flashes [107], and osteoporosis [109]. While musculoskeletal and vasomotor symptoms usually cease after ET discontinuation, thromboembolic events as well as osteoporosis are side effects with a long-term influence. Additionally, although, in general, ET is one of the best tolerable cancer treatments available, this specific side effect profile often leads to non-compliance [110] and/or non-persistence [111–113].

With the advent of combination therapies, new AEs were introduced into ET’s toxicity profile. Under everolimus, for instance, patients may develop stomatitis [41]. In those treated with alpelisib, hyperglycemia and rashes are the most common side ef-
fects [52]. Regarding the three CDK4/6 inhibitors, toxicity profiles differ. The rate of grade three/four neutropenia varies depending on the substance, but nevertheless appears in all three CDK4/6 inhibitors. However, there are also substance-specific AEs, such as gastrointestinal toxicities, including diarrhea under abemaciclib, or QTc prolongations under ribociclib [114]. These novel side effect profiles do not seem to affect the QoL in patients with a CDK4/6 inhibitor [115–117]; however, they might pose a challenge for treatment management and possibly adherence to these long-term therapies.

Persistence under adjuvant endocrine monotherapy has been investigated in several studies. After one year of letrozole, 13% of eBC patients will already have terminated treatment [118]. Other studies report that almost 50% of women discontinue adjuvant ET with tamoxifen or an AI within the first years of treatment [119]. However, compliance, i.e., whether the intake of the medication is in accordance with a physician’s prescription, and persistence, meaning the intake of the prescribed medication for the recommended duration, both contribute to the patient’s outcome. Studies have shown that patients who do not adhere to the recommended intake and duration of adjuvant ET are more likely to suffer from disease recurrence and have a worse prognosis [111,120]. Regarding terminology, since the definitions of the terms “compliance” and “persistence” vary [111,121,122], this in turn results in difficulties when comparing studies. The term “treatment adherence” is often used in the literature, as in the present study, to cover both [106,111,118].

Several studies have investigated the characteristics of patients who are non-adherent to ET and have tried to determine risk factors, especially in adjuvant therapy [106,111–113,118,119,121,123–127], as well as a small number in a metastatic treatment setting [128–130].

4.1. Endocrine Treatment Adherence in Early Breast Cancer Patients

In an adjuvant situation, age has been found to be a risk factor for non-adherence, with younger and older women in particular being at the highest risk [118,123,126,127]. Regarding body mass index (BMI), there are contradictory results, since some trials show no influence on therapy adherence [111,112], while in the Evaluate-TM study a low BMI was significantly associated with a higher discontinuation rate [118]. Furthermore, co-morbidities are shown to negatively influence persistence [118,123,131], but at the same time there are indications for a higher adherence rate in women with diabetes or depression [119]. The prior performance of radiation and chemotherapy, especially when including a taxane, seems to also be associated with women’s ET adherence, although it is not clear to date whether the influence is positive or negative [112,123–125]. Regarding tumor characteristics, there are results that suggest tumor stage and size are risk factors for non-adherence [124,126]. Contrary to other trials that did not confirm tumor grade as a risk factor [123,126], one study describes that a higher tumor grade is associated with a better ET persistence [118]. Treatment-associated risk factors mostly include ET side effects, such as musculoskeletal pain syndrome, vasomotor symptoms, or thromboembolic events as reasons for non-adherence [106,107,110–113]. While patients with musculoskeletal symptoms, mostly due to an AI therapy, are at the highest risk of non-adherence [106,111–113], those with pre-existing pain before the beginning of ET seem to be at an additional risk [113], since these women indicate even higher pain values [132].

4.2. Endocrine Treatment Adherence in Advanced Breast Cancer Patients

According to the literature, which is scarce, the metastatic situation is similar, although one would expect a higher motivation in patients with a life-threatening disease to continue the recommended treatment. Persistence with palliative ET depends not only on age or the number of comorbidities [128], but also on the presence of ET-induced AEs and previous treatment behavior [129,130,133,134].
5. Upcoming Improvements in the Treatment of Early Breast Cancer

The above-mentioned resistance mechanisms play not only a role in the advanced therapy setting, but also for neo-/adjuvantly treated eBC patients. Substances already approved for aBC are now subject to eBC trials.

5.1. CDK4/6 Inhibitors as a Possible New Cornerstone

CDK4/6 inhibitors have been investigated in high- and intermediate-risk eBC patients in studies of one to three years in combination with neo-/adjuvant ET with the aim to enhance the DFS rate (Table 3). However, the addition of one year of palbociclib to adjuvant ET in women with residual disease after neoadjuvant chemotherapy, as in the PenelopeB trial, did not improve DFS [135]. Neither did two years of palbociclib in patients with stage II–III disease in the PALLAS trial [136]. Two years of abemaciclib, in contrast, delivered in the primary outcome analysis of the monarchE trial, where women with node-positive eBC and a high-risk profile received the CDK4/6 inhibitor in addition to ET, positive results. While under ET alone after a median follow-up of 19 months, 89.3% of eBC patients were cancer-free, under abemaciclib it was a total of 92.3% (HR 0.71; 95% CI 0.58–0.87; and \( p = 0.0009 \)) [137]. With 27 months of median follow-up the invasive DFS benefit was maintained (HR 0.70; 95% CI 0.59–0.82; and \( p < 0.0001 \)) [138]. On this basis abemaciclib has been approved by the FDA for the treatment of patients with hormone-receptor-positive, HER2-negative, node-positive eBC at a high risk of recurrence and a Ki-67 score of \( \geq 20\% \). Results from the NATALEE trial with adjuvant ribociclib for a total of three years in high-and intermediate-risk eBC patients [139] are expected in the near future, which will help investigate whether the significant OS benefit seen in the MONALEESA-2/-3/-7 trials for aBC is transferable to the early treatment setting.

5.2. CDK4/6 Inhibitors Instead of Neo-/Adjuvant Chemotherapy

Even more interesting than the adjuvant use of CDK4/6 inhibitors together with ET is the vision of this combination replacing neo-/adjuvant chemotherapy. The phase II CORALLEEN study compared neoadjuvant ET with six cycles of letrozole and ribociclib to four cycles of a chemotherapy regime containing anthracycline and taxane. At the time of surgery, many of the tumors initially classified as luminal B were then measured to be luminal A tumors [140]. Neoadjuvant abemaciclib within the phase II neoMONARCH trial also demonstrated a certain potential of cell cycle arrest and immune activation [141], as did palbociclib in the neoadjuvant phase II trials neoPAL [142] and neoPalAna [143]. Larger phase II trials, such as CARABELA with abemaciclib or Appalaches with palbociclib [56], and the phase III study ADAPTcycle with ribociclib [144] will yield more information about the comparability of chemotherapy with a CDK4/6-inhibitor-based treatment with regard to efficacy and safety.

5.3. Further Approaches

Since the present review focuses on hormone-receptor-positive, HER2-negative BC, Table 3 provides an overview of the key ongoing trials that include a CDK4/6 inhibitor in the adjuvant treatment of this specific tumor type. However, CDK4/6 inhibitors are also being investigated in several combinational regimes for HER2-positive, HER2-low, or HER2-enriched [145] disease, but this is not the subject of this manuscript.

The role of PI3K inhibitors in eBC remains unclear. LORELEI, a phase II trial, was initiated to investigate the efficacy of taselisib combined with letrozole in the neoadjuvant ET setting. An objective response due to the addition of this PI3K inhibitor was demonstrated, but it was not sufficient enough to be recommended [146]. Alpelisib, in contrast to its efficacy in aBC, did not show any benefit when added to neoadjuvant ET in the NEO-ORB trial [147]. The development of the newer PI3K inhibitors inavolisib, copanlisib, and gedatolisib will reveal more about their potential significance for eBC.
### Table 3. Selection of key ongoing CDK4/6 inhibitor trials on hormone-receptor-positive, HER2-negative eBC (in alphabetical order; based on clinicaltrials.gov, accessed on 22 September 2021) [56].

| CDK4/6 Inhibitor | Abemaciclib | Dalpiciclib | Palbociclib | Ribociclib |
|------------------|-------------|-------------|-------------|-----------|
| **Study name**   | ADAPTlate   | CARABELA    | monarchE    | POETIC-A  |
| **Study code**   | NCT04565054 | NCT04293393 | NCT03155997 | NCT04584853 |
| **Phase**        | III         | II          | III         | II        |
| **Brief study summary** | Adjuvant abemaciclib + SOC ET vs. SOC ET | Adjuvant abemaciclib + SOC ET vs. SOC ET | Adjuvant palbociclib + SOC ET vs. chemotherapy followed by SOC ET | Adjuvant ribociclib + SOC ET vs. continuous ribociclib + SOC ET |
| **Main patient population criteria** | High risk Pre- and postmenopausal Female only | High and intermediate risk Pre- and postmenopausal Female only | High risk ≥70 years old Male patients allowed | Adjuvant intermittent ribociclib + SOC ET vs. continuous ribociclib + SOC ET |
| **Randomization** | 1:1         | 1:1         | 1:1         | 3:2       |
| **Duration of CDK4/6i intake** | 2 years     | 1 year      | 2 years     | 1 year    |
| **Number of patients** | 1250        | 200         | 5637        | 1070      |
| **Primary endpoint** | iDFS        | RCB         | iDFS        | Safety    |

**HER2:** human epidermal growth factor receptor 2; **CDK4/6i:** CDK4/6 inhibitor; **etDNA:** circulating tumor DNA; **eBC:** early breast cancer; **D-RFI:** distant recurrence-free interval; **ET:** endocrine treatment; **iDFS:** invasive disease-free survival; **MRD:** minimal residual disease; **RCB:** residual cancer burden; and **SOC:** standard of care. 1 Further trials with palbociclib in eBC, such as PenelopeB [135] and PALLAS [136], are not listed here due to already reported negative results. 2 Data unknown at the time of writing this manuscript.
Oral SERDS are also not only the subject of aBC trials but are analyzed in patients with eBC as well (Table 2). The phase III AMEERA-6 study, for instance, evaluates amcenestrant versus tamoxifen for postmenopausal women, with hormone-receptor-positive eBC unable to continue adjuvant AI therapy [148]. Giredestrant is being compared to physicians’ choices of ET in women with hormone-receptor-positive, HER2-negative eBC within the phase III lidERA trial [149]. These trials will show whether oral SERDs can become established substances of adjuvant ET.

Moreover, in BRCA-mutated patients with hormone-receptor-positive disease, there is also evidence that PARP inhibitors may enhance ET efficacy through a synergistic effect, since BRCA mutations have been linked to transcriptional function of hormone receptors [150,151]. The OlympiA trial is the first to show a benefit in DFS in women with HER2-negative eBC and a BRCA1/2 mutation receiving one year of adjuvant olaparib. The 3-year DFS of the total population was 85.9% in the olaparib group and 77.1% in the placebo group (HR 0.58; 99.5% CI 0.41–0.82; and \( p < 0.001 \)). However, a significant difference in OS rates could not be demonstrated. Looking only at hormone-receptor-positive, HER2-negative eBC patients who received olaparib for one year in addition to ET, compared to those included after adjuvant chemotherapy on the basis of node-positivity (HR 1.36; 95% CI 0.41–4.71), the subgroup of women who were enrolled due to residual disease after neoadjuvant chemotherapy benefitted the most (HR 0.52; 95% CI 0.25–1.04) [152]. Particularly in this patient population, combinational treatments might therefore be of interest in the future.

However, to be effective, each therapy requires patients’ adherence, especially in view of the cost–benefit ratio of novel substances and known unsatisfying adherence rates of standard ET. Therefore, to ensure women’s compliance and persistence and to improve their outcome with the help of expensive combinational regimens, the necessity of patients’ understanding of their recurrence risk, compliance programs, and digital health solutions, continuous treatment and side effect monitoring as well as a healthy patient–physician relationship will gain in importance with each novel therapy.

6. Conclusions

ET of BC, in both an early and advanced setting, has existed for several decades, and has consisted of the basic substances tamoxifen, an AI, or fulvestrant. Prolonging overall survival in aBC and now also entering the eBC treatment setting, CDK4/6 inhibitors will be the first novel substances to revolutionize this therapy area over the coming decades. Despite ET adherence rates being in need of improvement, in general it is one of the best tolerable cancer therapies available. Continuous investigation serves to improve patients’ outcomes and modernizes the current standard of care. Considering several recent successes in treatment efficacy, the rapid development of new drugs in the past few years, and their prompt implementation in treatment guidelines, the continuous improvement of ET is already a reality.

Author Contributions: Conceptualization, N.N. and P.A.F.; methodology, N.N. and P.A.F.; investigation, N.N. and P.A.F.; writing—original draft preparation, N.N.; writing—review and editing, N.N. and P.A.F.; visualization, N.N.; supervision, N.N. and P.A.F.; project administration, N.N. and P.A.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: N.N. is currently an employee of Novartis and has received travel support from Novartis and TEVA in the past. P.A.F. reports grants from Novartis, BioNTech, and Cepheid, as well as personal fees from Novartis, Roche, Pfizer, Lilly, Celgene, Daiichi-Sankyo, TEVA, AstraZeneca, Merck Sharp & Dohme, Myelo Therapeutics, Macrogenics, Eisai, and Puma.
References

1. Beatson, G. On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases. Lancet 1896, 148, 162–165. [CrossRef]

2. Early Breast Cancer Trialsists’ Collaborative Group; Davies, C.; Godwin, J.; Gray, R.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; Pan, H.C.; Taylor, C.; et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011, 378, 771–784. [PubMed]

3. Hammond, M.E.H.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J. Clin. Oncol. 2010, 28, 2784–2795. [CrossRef] [PubMed]

4. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N. Engl. J. Med. 2001, 344, 783–792. [CrossRef] [PubMed]

5. Mouridsen, H.; Gershanofovich, M.; Sun, Y.; Pérez-Carrión, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H.P.; Jänicke, F.; et al. Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women with Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2001, 19, 2596–2606. [CrossRef]

6. Nabholtz, J.; Buzdar, A.; Pollak, M.; Harwin, W.; Burton, G.; Mangalik, A.; Steinberg, M.; Webster, A.; Von Euler, M. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial. J. Clin. Oncol. 2000, 18, 3758–3767. [CrossRef]

7. Rugo, H.S.; Rumble, R.B.; Macrae, E.; Barton, D.L.; Connolly, H.K.; Dickler, M.N.; Fallowfield, L.; Fowble, B.; Ingle, J.N.; Jahanzeb, M.; et al. Endocrine Therapy for Hormone-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J. Clin. Oncol. 2016, 34, 3069–3103. [CrossRef]

8. Early Breast Cancer Trialsists’ Collaborative Group; Dowsett, M.; Forbes, J.F.; Bradley, R.; Ingle, J.; Aihara, T.; Bliss, J.; Boccardo, F.; Coates, A.; Coombes, R.C.; et al. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet 2015, 385, 1341–1352.

9. Early Breast Cancer Trialsists’ Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst. Rev. 2001, CD000486.

10. Ditsch, N.; Kolberg-Liedtke, C.; Friedrich, M.; Jackisch, C.; Albert, U.-S.; Banys-Paluchowski, M.; Bauerfeind, I.; Blohm, J.-U.; Budach, W.; Dall, P.; et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care 2021, 16, 214–227. [CrossRef]

11. Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.M.; Sahmoud, T. ATAC Trialsists’ Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002, 359, 2131–2139. [CrossRef] [PubMed]

12. Thürlimann, B.; Keshaviah, A.; Coates, A.S.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Rabaglio, M.; et al. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. N. Engl. J. Med. 2005, 353, 2747–2757. [CrossRef]

13. Colleoni, M.; Giobbie-Hurder, A.; Regan, M.M.; Thürlimann, B.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Láng, I.; Smith, I.; et al. Analyses Adjusting for Selective Crossover Show Improved Overall Survival with Adjuvant Letrozole Compared with Tamoxifen in the BIG 1-98 Study. J. Clin. Oncol. 2011, 29, 1117–1124. [CrossRef] [PubMed]

14. Coombs, R.C.; Hall, E.; Gibson, L.J.; Paridaens, R.; Jassem, J.; DeLozier, T.; Jones, S.E.; Alvarez, I.; Berti, G.; Ortmann, O.; et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. N. Engl. J. Med. 2004, 350, 1081–1092. [CrossRef]

15. Jonat, W.; Gnant, M.; Boccard, F.; Kaufmann, M.; Rubagotti, A.; Zuna, I.; Greenwood, M.; Jakesz, R. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol. 2006, 7, 991–996. [PubMed]

16. Bruksý, A.M.; Dickler, M.N. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. Oncologist 2018, 23, 528–539. [CrossRef]

17. Mills, J.N.; Ruttovskiy, A.C.; Giordano, A. Mechanisms of resistance in estrogen receptor positive breast cancer: Overcoming resistance to tamoxifen/aromatase inhibitors. Curr. Opin. Pharmacol. 2018, 41, 59–65. [CrossRef]

18. Cole, M.P.; Jones, C.; Todd, I.D.H. A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474. Br. J. Cancer 1971, 25, 270–275. [CrossRef]

19. Jordan, V.C. Tamoxifen: A most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2003, 2, 205–213. [CrossRef]

20. Davies, C.; Pan, H.; Godwin, J.; Gray, R.; Arriagada, R.; Raina, V.; Abraham, M.; Alencar, V.H.M.; Badran, A.; Bonfill, X.; et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381, 805–816. [CrossRef]

21. Gray, R.G.; Rea, D.; Handley, K.; Bowden, S.J.; Perry, P.; Earl, H.M.; Poole, C.J.; Bates, T.; Chetyawardana, S.; Dewar, J.A.; et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J. Clin. Oncol. 2013, 31, 5. [CrossRef]
22. Thomssen, C.; Balic, M.; Harbeck, N.; Gnant, M.S. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. *Breast Cancer* 2021, 16, 135–143. [CrossRef]

23. Pagani, O.; Francis, P.; Fleming, G.F.; Walley, B.A.; Viale, G.; Colleoni, M.; Láng, I.; Gómez, H.L.; Tondini, C.; Pinotti, G.; et al. Absolute Improvements in Freedom from Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results from TEXT and SOFT. *J. Clin. Oncol.* 2020, 38, 1293–1303. [CrossRef] [PubMed]

24. Francis, P.A.; Pagani, O.; Fleming, G.F.; Walley, B.A.; Colleoni, M.; Láng, I.; Gómez, H.L.; Tondini, C.A.; Ciruelos, E.; Burstein, H.J.; et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N. Engl. J. Med.* 2018, 379, 122–137. [CrossRef] [PubMed]

25. Saha, P.; Regan, M.M.; Pagani, O.; Francis, P.; Walley, B.A.; Ribi, K.; Bernhard, J.; Luo, W.; Gómez, H.L.; Burstein, H.J.; et al. Treatment Efficacy, Adherence, and Quality of Life among Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. *J. Clin. Oncol.* 2017, 35, 3113–3122. [CrossRef] [PubMed]

26. Santen, R.J.; Brodie, H.; Simpson, E.R.; Siltert, P.K.; Brodie, A. History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target. *Endocr. Rev.* 2009, 30, 343–375. [CrossRef]

27. De Placido, S.; Gallo, C.; De Laurentiis, M.; Bisagni, G.; Arpino, G.; Sarobba, M.G.; Riccardi, F.; Russo, A.; Del Mastro, L.; Cogoni, A.A.; et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): A randomised, phase 3 trial. *Lancet Oncol.* 2018, 19, 474–485. [CrossRef]

28. Smith, I.; Yardley, D.; Burris, H.A.; De Boer, R.; Amadori, D.; McIntyre, K.; Ejertsen, B.; Gnant, M.; Jonat, W.; Pritchard, K.I.; et al. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients with Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FAICE) Trial. *J. Clin. Oncol.* 2017, 35, 1041–1048. [CrossRef]

29. Goss, P.E.; Ingle, J.N.; Pritchard, K.I.; Robertson, J.F.R.; Musset, H.; Gralow, J.; Gelmon, K.; Whelan, T.; Strasser-Weippl, K.; Rubin, S.; et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. *N. Engl. J. Med.* 2016, 375, 209–219. [CrossRef]

30. Xu, L.; Zhang, Z.; Xiang, Q.; Liu, Q.; Duan, X.; Liu, Y.; Cui, Y. Extended Adjuvant Therapy with Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials. *Clin. Breast Cancer* 2019, 19, e578–e588. [CrossRef]

31. Blok, E.J.; Kroep, J.R.; Meershoek-Klein Kraneberg, E.; Duijm-de Carpentier, M.; Putter, H.; van den Bosch, J.; Maartense, E.; et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer: Results of the IDEAL Trial (BOOG 2006-05). *J. Natl. Cancer Inst.* 2018, 110, 40–48. [CrossRef]

32. Mamounas, E.P.; Bandos, H.; Lembersky, B.C.; Jeong, J.-H.; Geyer, C.E.; Rastogi, P.; Fehrenbacher, L.; Graham, M.L.; Chia, S.K.; Blufsky, A.M.; et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal women with hormone receptor-positive advanced breast cancer (NRG Oncology/NSABP B-42): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019, 20, 88–99. [CrossRef]

33. Jerusalem, G.; Farah, S.; Courtois, A.; Chirgwin, J.; Aebi, S.; Karlsson, P.; Neven, P.; Hitre, E.; Graa, M.P.; Simoncini, E.; et al. Continuous versus intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. *Ann. Oncol.* 2021, 32, 1256–1266. [CrossRef] [PubMed]

34. Lee, C.I.; Goodwin, A.; Wilcken, N. Fulvestrant for hormone-sensitive metastatic breast cancer. *Cochrane Database Syst. Rev.* 2017, 1, CD011093. [CrossRef] [PubMed]

35. Xie, Y.; Li, Y.; Zhang, Y.; Zhang, S.; Li, W.; Guan, X.; Zhao, Y.; Gong, C.; Hu, X.; Zhang, J.; et al. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women with Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study. *Clin. Breast Cancer* 2019, 19, e452–e458. [CrossRef]

36. Robertson, J.F.R.; Jiang, Z.; Di Leo, A.; Ohno, S.; Pritchard, K.I.; Ellis, M.; Bradbury, I.; Campbell, C. A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. *Breast Cancer* 2019, 26, 703–711. [CrossRef]

37. Cardoso, F.; Costa, A.; Norton, L.; Senkus, E.; Aapro, M.; André, F.; Barrios, C.; Bergh, J.; Biganzoli, L.; Blackwell, K.; et al. ESO-ESMO 2nd international guidelines for advanced breast cancer (ABC2). *Breast* 2014, 23, 489–502. [CrossRef] [PubMed]

38. Maass, N.; Ostermann, H.; Possinger, K.; Klein, P.; Tesch, H.; Mühlenhoff, L.; Bauerschlag, D. ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany. *Breast Cancer* 2019, 14, 401–408. [CrossRef] [PubMed]

39. Li, M.; Xiong, Y.; Liao, C.; He, Y.; Duan, S.; Yi, F.; Wei, Y.; Zhang, W. Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: A meta-analysis of randomized controlled trials. *Breast Cancer Res. Treat.* 2020, 180, 269–278. [CrossRef]

40. Beck, J.T.; Hortobagyi, G.N.; Campone, M.; Lebrun, F.; Deleu, I.; Rugo, H.S.; Pistilli, B.; Masuda, N.; Hart, L.; Melichar, B.; et al. Everolimus plus exemestane as first-line therapy in HR(+) HER2(−) advanced breast cancer in BOLERO-2. *Breast Cancer Res. Treat.* 2014, 143, 459–467. [CrossRef]

41. Tesch, H.; Stoeter, O.; Decker, T.; Kurbacher, C.M.; Marmé, F.; Schneweiss, A.; Mundhenke, C.; Distelrath, A.; Fasching, P.A.; Lux, M.P.; et al. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. *Int. J. Cancer* 2019, 144, 877–885. [CrossRef] [PubMed]
Piccart, M.; Hortobagyi, G.N.; Campone, M.; Pritchard, K.I.; Lebrun, E.; Ito, Y.; Noguchi, S.; Perez, A.; Rugo, H.S.; Deleu, I.; et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2. Ann. Oncol. 2014, 25, 2357–2362. [CrossRef] [PubMed]

Schmid, P.; Zaisser, M.; Harper-Wynne, C.; Ferreira, M.; Dubey, S.; Chan, S.; Makris, A.; Nensadze, G.; Brunt, A.M.; Kuemmel, S.; et al. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019, 5, 1556–1564. [CrossRef]

Yi, Z.; Liu, B.; Sun, X.; Rong, G.; Wang, W.; Li, H.; Guan, X.; Li, L.; Zhai, J.; Li, C.; et al. Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. Breast 2020, 52, 17–22. [CrossRef] [PubMed]

Baselga, J.; Im, S.-A.; Iwata, H.; Cortes, J.; DE Laurentiis, M.; Jiang, Z.; Arteaga, C.L.; Jonat, W.; Clemons, M.; Ito, Y.; et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017, 18, 904–916. [CrossRef]

Di Leo, A.; Johnston, S.; Lee, K.S.; Ciruelos, E.; Lønning, P.E.; Janni, W.; O'Regan, R.; Mouret-Reynier, M.A.; Kalev, D.; Egle, D.; et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018, 19, 87–100. [CrossRef]

Campone, M.; Im, S.-A.; Iwata, H.; Clemons, M.; Ito, Y.; Awada, A.; Chia, S.; Jagiello-Gruszfeld, A.; Pistilli, B.; Tseng, L.-M.; et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Eur. J. Cancer 2018, 103, 147–154. [CrossRef]

Dent, S.; Cortés, J.; Im, Y.-H.; Diéras, V.; Harbeck, N.; Krop, I.; Wilson, T.; Cui, N.; Schimmoller, F.; Hsu, J.; et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: The SANDPIPER trial. Ann. Oncol. 2021, 32, 197–207. [CrossRef] [PubMed]

André, F.; Ciruelos, E.; Juric, D.; Loibl, S.; Campone, M.; Mayer, I.A.; Rubovszky, G.; Yamashita, T.; Kaufman, B.; Lu, Y.S.; et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Final overall survival results from SOLAR-1. Ann. Oncol. 2021, 32, 208–217. [CrossRef] [PubMed]

Ciruelos, E.M.; Rugo, H.S.; Mayer, I.A.; Levy, C.; Forget, F.; Delgado Mingorance, J.I.; Safra, T.; Masuda, N.; Park, Y.H.; Juric, D.; et al. Patient-Reported Outcomes in Patients with PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer from SOLAR-1. J. Clin. Oncol. 2021, 39, 2005–2015. [CrossRef]

André, F.; Ciruelos, E.; Rubovszky, G.; Campone, M.; Loibl, S.; Rugo, H.S.; Iwata, H.; Conte, P.; Mayer, I.A.; Kaufman, B.; et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 2019, 380, 1929–1940. [CrossRef] [PubMed]

Rugo, H.S.; Lerebours, F.; Ciruelos, E.; Druilhinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y.H.; Prat, A.; Bachelot, T.; Juric, D.; et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021, 22, 489–498. [CrossRef]

Burstein, H.J.; Somerfield, M.R.; Barton, D.L.; Dorris, A.; Fallowfield, L.J.; Jain, D.; Korde, L.A.; Litton, J.K.; Macrè, E.R.; et al. Endocrine Therapy and Targeted Treatment for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J. Clin. Oncol. 2021, JCO2101392. [CrossRef] [PubMed]

Zhang, M.; Jiang, H.; Nussinov, R. PI3K inhibitors: Review and new strategies. Chem. Sci. 2020, 11, 5855–5865. [CrossRef] [PubMed]

Shor, R.E.; Dai, J.; Lee, S.; Pisarsky, L.; Matei, I.; Lucotti, S.; Lyden, D.; Bissell, M.J.; Ghajar, C.M. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings. Mol. Oncol. 2021. [CrossRef] [PubMed]

ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ (accessed on 22 September 2021).

Smyth, L.M.; Tamura, K.; Oliveira, M.; Ciruelos, E.M.; Mayer, I.A.; Sabin, M.P.; Biganzoli, L.; Ambrose, H.J.; Ashton, J.; Barnicle, A.; et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer. Clin. Cancer Res. 2019, 25, 2885–2895. [CrossRef]

Jones, R.H.; Casbard, A.; Carucci, M.; Cox, C.; Butler, R.; Alchami, F.; Madden, T.; Bale, C.; Bezeny, P.; Joffe, J.; et al. Fulvestrant plus capivasertib versus placebo before relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (FAKTION): A multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020, 21, 345–357. [CrossRef]

Turner, N.; Howell, S.; Jhaveri, K.; Gomez, H.; Toi, M.; Hu, X.; Loibl, S.; Rugo, H.S.; Ni, P.; De Bruin, E.; et al. Buparlisib plus capivasertib versus placebo and fulvestrant in patients with HR+ HER2-breast cancer (CAPTello-291). Ann. Oncol. 2020, 31, S388–S389. [CrossRef]

Dent, R.; Kim, S.-B.; Oliveira, M.; Barrios, C.; O’Shaughnessy, J.; Isakoff, S.J.; Saji, S.; Freitas-Junior, R.; Philco, M.; Bondarenko, I.; et al. Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/ AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): Primary results from IPATunity130 Cohort A. Cancer Res. 2020, 81, GS3-04. [CrossRef]
Cancers 2021, 13, 5643

61. Turner, N.; Dent, R.; O’Shaughnessy, J.; Kim, S.-B.; Isakoff, S.; Barrios, C.; Saiji, S.; Bondarenko, I.; Nowecki, Z.; Lian, Q.; et al. 283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial. Ann. Oncol. 2020, 31, S354–S355. [CrossRef]

62. Finn, R.S.; Dering, J.; Conklin, D.; Kalous, O.; Cohen, D.J.; Desai, A.J.; Ginther, C.; Atefi, M.; Chen, I.; Fowst, C.; et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11, R77. [CrossRef]

63. Miller, T.W.; Balko, J.M.; Fox, E.M.; Ghazoui, Z.; Dunbier, A.; Anderson, H.; Dowsett, M.; Jiang, A.; Smith, R.A.; Maira, S.M.; et al. ERLin-2-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011, 1, 338–351. [CrossRef]

64. Turner, N.C.; Neven, P.; Loibl, S.; Andre, F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet 2016, 389, 2403–2414. [CrossRef]

65. Slamon, D.J.; Neven, P.; Chia, S.; Paschinger, P.A.; De Laurentiis, M.; Im, S.A.; Petraglou, K.; Bianchi, G.V.; Esteve, F.J.; Martin, M.; et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J. Clin. Oncol. 2018, 36, 2465–2472. [CrossRef] [PubMed]

66. Finn, R.S.; Martin, M.; Rugo, H.S.; Jones, S.; Im, S.-A.; Gelmon, K.; Harbeck, N.; Lipatov, O.N.; Walshe, J.M.; Moulder, S.; et al. Palbociclib and Letrozole in Advanced Breast Cancer. N. Engl. J. Med. 2016, 375, 1925–1936. [CrossRef] [PubMed]

67. Cristofanilli, M.; Turner, N.C.; Bondarenko, I.; Ro, J.; Im, S.-A.; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; et al. Fulvestrant plus palbociclib versus placebo plus letrozole for hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016, 17, 425–439. [CrossRef]

68. Sledge, J.G.; Toi, M.; Neven, P.; Sohn, J.; Inoue, K.; Pivot, X.; Burdavea, O.; Okera, M.; Masuda, N.; Kaufman, P.A.; et al. MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+ /HER2– Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J. Clin. Oncol. 2017, 35, 2875–2884. [CrossRef]

69. Johnston, S.; Martin, M.; Di Leo, A.; Im, S.-A.; Awada, A.; Forrester, T.; Frenzel, M.; Hardebeck, M.C.; Cox, J.; Barriga, S.; et al. MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019, 5, 1–8. [CrossRef]

70. Tripathy, D.; Im, S.-A.; Colleoni, M.; Franke, E.; Bardia, A.; Harbeck, N.; Hurvitz, S.A.; Chow, L.; Sohn, J.; Lee, K.S.; et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol. 2018, 19, 904–915. [CrossRef]

71. Hortobagyi, G.; Stemmer, S.; Burris, H.; Yap, Y.S.; Sonke, G.; Paluch-Shimon, S.; Campone, M.; Petraglou, K.; Blackwell, K.; Winer, E.; et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann. Oncol. 2018, 29, 1541–1547. [CrossRef]

72. Giuliano, M.; Schettini, F.; Rognoni, C.; Milani, M.; Jerusalem, G.; Bachelot, T.; De Laurentiis, M.; Thomas, G.; De Placido, P.; Arpino, G.; et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and network meta-analysis. Lancet Oncol. 2019, 20, 1360–1369. [CrossRef]

73. Schneeweiss, A.; Ettl, J.; Luftenr, D.; Beckmann, M.W.; Belleville, E.; Fasching, P.A.; Fehm, T.N.; Geberth, M.; Haberle, L.; Hadji, P.; et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer—Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020, 54, 88–95. [CrossRef]

74. Hartkopf, A.D.; Huober, J.; Volz, B.; Nabieva, N.; Taran, F.-A.; Schvitulla, J.; Overkamp, F.; Kolberg, H.-C.; Hadji, P.; Tesch, H.; et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors—Data from the German PRAEGNANT breast cancer registry. Breast 2018, 37, 42–51. [CrossRef]

75. Sledge, G.W., Jr.; Toi, M.; Neven, P.; Sohn, J.; Inoue, K.; Pivot, X.; Burdavea, O.; Okera, M.; Masuda, N.; Kaufman, P.A.; et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019, 6, 116–124. [CrossRef]

76. Turner, N.C.; Slamon, D.J.; Ro, J.; Bondarenko, I.; Im, S.-A.; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N. Engl. J. Med. 2018, 379, 1926–1936. [CrossRef]

77. Jimenez, M.M.; Zielinski, C.; Ruiz-Borrego, M.; Carrasco, E.; Cisneros, E.; Muñoz, M.; Bermejo, B.; Margeli, M.; Csoszi, T.; Anton, A.; et al. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus placebo (CAP) in hormone-receptor+/HER2– metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study. Ann. Oncol. 2021, 32, S457–S458. [CrossRef]

78. Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.S.; Sonke, G.; Hart, L.; Campone, M.; Petraglou, K.; Winer, E.P.; Janni, W.; et al. Overall Survival Results from the Phase III MONALEESA-2 Trial of Postmenopausal Patients with HR+/HER2- Advanced Breast Cancer Treated with Endocrine Therapy +/– Ribociclib. Presented at 2021 European Society for Medical Oncology, Paris, France, 16–21 September 2021.

79. Slamon, D.J.; Neven, P.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.; Petraglou, K.; Bianchi, G.V.; Martin, M.; Nusch, A.; et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor
2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: Updated overall survival. *Ann. Oncol.* 2021, 32, 1015–1024. [CrossRef]

80. Tripathy, D.; Im, S.-A.; Colleoni, M.; Franke, F.; Bardia, A.; Harbeck, N.; Hurvitz, S.; Chow, L.; Sohn, J.; Lee, K.S.; et al. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+ /HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. *Cancer Res.* 2021, 81, PD2-04.

81. Sharifi, M.N.; Anandan, A.; Grogan, P.; O’Regan, R.M. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. *Cancer* 2020, 126, 3400–3416. [CrossRef]

82. Xu, B. Dalipiclib Extends Progression-Free Survival in HR+/HER2- Advanced Breast Cancer. *OncoList* 2021, 26 (Suppl. S3), S9–S10.

83. van Kruchten, M.; de Vries, E.G.; Glaudemans, A.W.; van Lanschot, M.C.; van Faassen, M.; Kema, I.P.; Brown, M.; Schroder, C.P.; de Vries, E.F.; Hoppers, G.A. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. *Cancer Discov.* 2015, 5, 72–81. [CrossRef] [PubMed]

84. Lai, A.C.; Crews, C.M. Induced protein degradation: An emerging drug discovery paradigm. *Nat. Rev. Drug Discov.* 2017, 16, 101–114. [CrossRef] [PubMed]

85. Liang, J.; Zbieg, J.R.; Blake, R.A.; Chang, J.H.; Daly, S.; DiPasquale, A.G.; Friedman, L.S.; Gelzleichter, T.; Gill, M.; Giltzne, J.M.; et al. Exceptional Preclinical Profile for ER+ Breast Cancer. *J. Med. Chem.* 2021, 64, 11841–11856. [CrossRef]

86. Shomali, M.; Cheng, J.; Sun, F.; Koundinya, M.; Guo, Z.; Hebert, A.T.; McManus, J.; Levit, M.N.; Hoffmann, D.; Courjaud, A.; et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. *Mol. Cancer Ther.* 2020, 21, 250–262. [CrossRef]

87. Robertson, J.F.; Evans, A.; Henschen, S.; Kirwan, C.C.; Jahan, A.; Kenny, L.M.; Dixon, J.M.; Schmid, P.; Kothari, A.; et al. AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. *Mol. Cancer Ther.* 2021, 20, 3510–3518. [CrossRef] [PubMed]

88. Chandarlapaty, S.; Linden, H.M.; Neven, P.; Petrakova, K.; Bardiz, A.; Kabos, P.; Braga, S.; Boni, V.; Pelekanou, V.; Tern, O.L.; et al. A randomized, window of opportunity study comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ breast cancer. *Cancer Res.* 2020, 80, 4242–4249. [CrossRef]

89. Martin, M.; et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N. Engl. J. Med.* 2017, 376, 523–533. [CrossRef] [PubMed]

90. Hamilton, E.P.; Patel, M.R.; Armstrong, A.C.; Baird, R.D.; Jhaveri, K.; Hoch, M.; Klinowska, T.; Lindemann, J.; Morgan, S.R.; Schiavon, G.; et al. AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. *Cancer Discov.* 2021, 11, 1619–1630. [CrossRef] [PubMed]

91. Martin, M.; et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N. Engl. J. Med.* 2017, 376, 523–533. [CrossRef] [PubMed]
118. Nabiева, Н.; Келлер, С.; Фехм, Т.; Хаберле, Л.; де Вааль, Я.; Резай, М.; Байер, Б.; Баке, Г.; Колберг, Х.-С.; Гуггенбергер, М.; и др. Влияние признаков заболевания на перспективу терапии с летрозолом в постменопаузе у женщин с раком груди: Результаты проспективного изучения Evaluate-TM с 3941 пациентов. Ann. Oncol. 2018, 29, 186–192. [CrossRef] [PubMed]

119. Хаджі, П.; Зиллер, В.; Кывернитакис, І.; Брауер, М.; Хас, Г.; Смидт, Н.; Корстів, К. ПERSISTENCE: влияние на пациентов с раком груди, получавших долгосрочную терапию, была проведена ретроспективная метаанализ исследования. Breast Cancer Res. Treat. 2013, 138, 185–191. [CrossRef] [PubMed]

120. Хершман, Д.Л.; Шао, Т.; Куши, Л.; Букундо, Д.; Тсай, В.Я.; Фехенбахер, Л.; Кван, М.; Гомез, С.Л.; Неугут, А.И. Раннее прекращение терапии и непрерывность терапии андрогеном с повышенной морбидностью с увеличением летальности в грудных заболеваниях. Breast Cancer Res. Treat. 2011, 126, 529–537. [CrossRef]

121. Партридж, А.Х.; ЛаФонтан, А.; Мейер, Е.; Уайнер, Е.; Аснис-Альбозек, А. Адгезия к начальной андрогенотерапии у женщин с ранней стадией рака груди. J. Clin. Oncol. 2008, 26, 556–562. [CrossRef] [PubMed]

122. Крамер, Я.А.; Рой, А.; Бёррелл, А.; Фэайлчайд, С.К.; Фулдорф, Д.А.; Вонг, П.Х. Согласие и установление терапии: Терминология и определение. Value Health 2008, 11, 44–47. [CrossRef]

123. Хершман, Д.Л.; Куши, Л.; Шао, Т.; Букундо, Д.; Керсненбаум, А.; Фехенбахер, Л.; Гомез, С.Л.; Милес, С.; Неугут, А.И. Раннее прекращение терапии и непрерывность терапии андрогеном в ходе исследования. J. Clin. Oncol. 2010, 28, 4120–4128. [CrossRef]

124. Брито, С.; Портела, М.С.; Де Вассенкало, М.Т.Л. Терапия гормонов для хронических состояний у женщин с раком груди. BMC Cancer 2014, 14, 397. [CrossRef]

125. Кемп, А.; Пизм, Д.Б.; Саундерс, С.; Бойл, Я.; Булсара, М.; Малацова, Е.; Рогхед, Е.Е. Снижение длительности гормонотерапии для рака груди: Кто рискует в клинике? Springerplus 2014, 3, 282. [CrossRef] [PubMed]

126. Вигар, А.; Альхжен, Я.; Холмвист, М.; Фондер, Т.; Адольссон, Я.; Линдман, Х.; Бергквист, Л.; Ламбе, М. Адгезия и прекращение терапии андрогеном в ходе лечения рака груди: Результаты популяционного исследования. Breast Cancer Res. Treat. 2012, 133, 367–373. [CrossRef]

127. Тинари, Н.; Фаница, Л.; Ромеро, М.; Гамбала, Е.; Москетти, Л.; Ваккаро, А.; Семинара, П.; Лонго, Ф.; Гори, С.; Вици, П.; и др. Идентификация подгрупп ранних больных раком груди с риском неприемлемости к гормонотерапии: Результаты исследования. Clin. Breast Cancer 2015, 15, e131–e137. [CrossRef]

128. Аддеро, Р.; Иодич, П.; Майорино, Л.; Фебраро, А.; Инконорато, П.; Писано, А.; Бинано, М.; Мабилия, Р.; Риккарди, Ф.; Дел Прете, С. Согласие и установление терапии в оральной эндоцерной терапии у женщин с метастазированным раком груди: Экзаманьяка Групп Студи. Breast J. 2015, 21, 326–328. [CrossRef]

129. Гут, У.; Хуан, Д.Ж.; Шотзау, А.; Смид, С.М. Использование паллиативной терапии в химиотерапии у пациентов с раком молочной железы: Ранний прогноз. Oncology 2016, 90, 1–9. [CrossRef] [PubMed]

130. Вальвьенер, М.; Набиеева, Н.; Фисуст, М.; Фехм, Т.; Де Вааль, Я.; Резай, М.; Байер, Б.; Баке, Г.; Колберг, Х.С.; Гуггенбергер, М.; и др. Пациент и туморные характеристики и их влияние на терапию с летрозолом в онкологических заболеваниях у пациентов с раком груди. BMC Cancer 2018, опубликовано.

131. Неугут, А.И.; Чонг, Ч.; Уорд, Ж.Д.; Аккордино, М.; Янг, Я.; Хершман, Д.Л. Непрерывность терапии для хронических условий и непрерывность к адгезии эндокринной терапии у женщин с раком груди. JAMA Oncol. 2016, 2, 1326–1332. [CrossRef] [PubMed]

132. Набиеева, Н.; Хаберле, Л.; Брукер, С.Ь.; Янни, В.; Волз, В.; Лоебберг, С.Р.; Хартковф, А.; Уорд, Ч.; Баке, Г.; Фридман, А.; и др. Влияние предшествующих суставных и мышечно-мышечных симптомов на развитие мускуло-сkeletal вредных симптомов опиодов в ходе лечения рака груди у ранних больных — результаты из предварительного исследования. J. Cancer 2018, опубликовано.

133. Робертсон, Ж.Р.; Бонденарко, И.; Тришкхина, Е.; Дворкин, М.; Панасци, Л.; Манихас, Х.; Шпакри, Я.; Кардона-Уерта, С.; Ченг, К.-Л.; Филко-Сала, М.Ж.; и др. Инъекция 500 мг против андрогенотерапии 1 мг для гормонотерапии-позитивного умеренного рака груди (ФАЛКОН): Международное, стандартизированное, двойное слепое, третье нивелирование. Lancet 2016, 388, 2997–3005. [CrossRef]

134. Вальвьенер, М.; Набиеева, Н.; Фисуст, М.; Фехм, Т.; Де Вааль, Я.; Резай, М.; Байер, Б.; Баке, Г.; Колберг, Х.С.; Гуггенбергер, М.; и др. Влияние пациента и туморных характеристик на терапию с летрозолом в онкологических заболеваниях у женщин с раком груди. Results of the prospective observational EvAluate-TM study. BMC Cancer 2019, 19, 611. [CrossRef]

135. Лоеб, С.; Марме, Ф.; Мартин, М.; Унчт, М.; Боннфой, Х.; Ким, С.-Ы.; Бёррелл, Х.; МакКарти, Н.; Олив, М.М.; Гельмон, К.; и др. Палбоксил для высокого риска инвазивного высокого инвазивного и HER2-отрицательного раннего рака груди — Результаты Ленепело-Б исследований. J. Clin. Oncol. 2021, 39, 1518–1530. [CrossRef]

136. Майер, Е.Л.; Дюек, А.С.; Мартин, М.; Рубовскы, Г.; Бурстайн, Х.Ж.; Белет-Эскера, М.; Миллер, К.Д.; Зденковски, Н.; Уайнер, Е.П.; Пфеилер, Г.; и др. Палбоксил с адгезией эндокринной терапии в раннем раке груди (PALLAS): Интерим анализ многоцентра, открытый-рандомизированный, фаза 3 исследование. Lancet Oncol. 2021, 22, 212–222. [CrossRef]

137. О’Шауннесси, Я.А.; Джонстон, С.; Харбек, Н.; Той, М.; Им, Я.-Н.; Реинш, М.; Шоа, З.; Лехтинен, П.Л.К.; Хуанг, К.-С.; Триякин, А.; и др. Сокращение Результаты первичного анализа инвазивного и HER2-негативных больных раком груди. Cancer Res. 2021, 81, GS1-01. [CrossRef]

138. Харбек, Н.; Растоги, П.; Мартин, М.; Толейн, С.; Шоа, З.; Фасхинг, П.; Хуанг, Ч.; Яллифе, Г.; Триякин, А.; Гойц, М.; и др. Адгезия abemaciclib с эндокринной терапией для высокого риска раннего рака груди: Обновленные данные и Ki-67 анализа из исследования monarchE. Ann. Oncol. 2021. [CrossRef]
139. Slamon, D.J.; Fasching, P.A.; Patel, R.; Verma, S.; Hurvitz, S.A.; Chia, S.K.L.; Crown, J.; Martin, M.; Barrios, C.H.; Spera, G.; et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (EBC). J. Clin. Oncol. 2019, 37, TPS597. [CrossRef]

140. Prat, A.; Saura, C.; Pascual, T.; Hernando, C.; Munoz, M.; Pare, L.; Farré, B.G.; Fernández, P.L.; Galván, P.; Chic, N.; et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): An open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020, 21, 33–43. [CrossRef]

141. Harbeck, N.; Gluz, O.; Christgen, M.; Graeser, M.; Hilpert, F.; Krauss, K.; Thill, M.; Warm, M.; Müller, V.; Braun, M.W.; et al. POTENT Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer. Clin. Cancer Res. 2020, 26, 566–580. [CrossRef] [PubMed]

142. Cottu, P.; D’Hondt, V.; Dureau, S.; Lerebours, F.; Desmoulins, I.; Heudel, P.; Duhoux, F.; Levy, C.; Mouret-Reynier, M.-A.; Dalenc, F.; et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann. Oncol. 2018, 29, 2334–2340. [CrossRef]

143. Slamon, D.J.; Fasching, P.A.; Patel, R.; Verma, S.; Hurvitz, S.A.; Chia, S.K.L.; Crown, J.; Martin, M.; Barrios, C.H.; Spera, G.; et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (EBC). J. Clin. Oncol. 2019, 37, TPS597. [CrossRef] [PubMed]

144. Harbeck, N.; Gluz, O.; Christgen, M.; Graeser, M.; Hilpert, F.; Krauss, K.; Thill, M.; Warm, M.; Müller, V.; Braun, M.W.; et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): An open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020, 21, 33–43. [CrossRef]

145. Mayer, I.A.; Prat, A.; Egle, D.; Blau, S.; Fidalgo, J.A.P.; Gnant, M.; Fasching, P.A.; Colleoni, M.; Wolff, A.; Winer, E.P.; et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. Press Release 4 June 2021. Available online: https://www.sanofi.com/en/media-room/press-releases/2021/2021-06-04-07-00-00-2241809 (accessed on 13 October 2021).

146. Mayer, I.A.; Prat, A.; Egle, D.; Blau, S.; Fidalgo, J.A.P.; Gnant, M.; Fasching, P.A.; Colleoni, M.; Wolff, A.; Winer, E.P.; et al. Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clin. Cancer Res. 2019, 25, 2975–2987. [CrossRef] [PubMed]

147. Cottu, P.; D’Hondt, V.; Dureau, S.; Lerebours, F.; Desmoulins, I.; Heudel, P.; Duhoux, F.; Levy, C.; Mouret-Reynier, M.-A.; Dalenc, F.; et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann. Oncol. 2018, 29, 2334–2340. [CrossRef]

148. Mayer, I.A.; Prat, A.; Egle, D.; Blau, S.; Fidalgo, J.A.P.; Gnant, M.; Fasching, P.A.; Colleoni, M.; Wolff, A.; Winer, E.P.; et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. Press Release 4 June 2021. Available online: https://www.sanofi.com/en/media-room/press-releases/2021/2021-06-04-07-00-00-2241809 (accessed on 13 October 2021).

149. Poly(ADP-ribose) Polymerase 1 Is a Key Regulator of Estrogen Receptor α-dependent Gene Transcription. J. Biol. Chem. 2013, 288, 11348–11357. [CrossRef] [PubMed]

150. Zhang, F.; Wang, Y.; Wang, L.; Luo, X.; Huang, K.; Wang, C.; Du, M.; Liu, F.; Luo, T.; Huang, D.; et al. Poly(ADP-ribose) Polymerase 1 Is a Key Regulator of Estrogen Receptor α-dependent Gene Transcription. J. Biol. Chem. 2013, 288, 11348–11357. [CrossRef] [PubMed]

151. Zhang, F.; Wang, Y.; Wang, L.; Luo, X.; Huang, K.; Wang, C.; Du, M.; Liu, F.; Luo, T.; Huang, D.; et al. Poly(ADP-ribose) Polymerase 1 Is a Key Regulator of Estrogen Receptor α-dependent Gene Transcription. J. Biol. Chem. 2013, 288, 11348–11357. [CrossRef] [PubMed]

152. Schiewer, M.J.; Goodwin, J.F.; Han, S.; Brenner, J.C.; Augello, M.A.; Dean, J.L.; Liu, F.; Planck, J.L.; Ravindranathan, P.; Chinnaiyan, A.M.; et al. Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discov. 2012, 2, 1134–1149. [CrossRef] [PubMed]

153. Schiewer, M.J.; Goodwin, J.F.; Han, S.; Brenner, J.C.; Augello, M.A.; Dean, J.L.; Liu, F.; Planck, J.L.; Ravindranathan, P.; Chinnaiyan, A.M.; et al. Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discov. 2012, 2, 1134–1149. [CrossRef] [PubMed]

154. Schiewer, M.J.; Goodwin, J.F.; Han, S.; Brenner, J.C.; Augello, M.A.; Dean, J.L.; Liu, F.; Planck, J.L.; Ravindranathan, P.; Chinnaiyan, A.M.; et al. Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discov. 2012, 2, 1134–1149. [CrossRef] [PubMed]

155. Schiewer, M.J.; Goodwin, J.F.; Han, S.; Brenner, J.C.; Augello, M.A.; Dean, J.L.; Liu, F.; Planck, J.L.; Ravindranathan, P.; Chinnaiyan, A.M.; et al. Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discov. 2012, 2, 1134–1149. [CrossRef] [PubMed]